DZHK financed and Associated Studies

SPIRonolactone In the Treatment for Heart Failure (SPIRIT-HF-DZHK8)

The SPIRIT-HF-DZHK8 study investigates whether the drug spironolactone can reduce the number of people with preserved ejection fraction who end up in hospital and the number of people who die from heart failure. Currently, there is no cure for this type of heart failure.

Previous studies with spironolactone have not yet given any clear results for people affected by preserved ejection fraction. The SPIRIT-HF study will differ to previous research because there will be only patients included conclusively diagnosed with poor dilation of the heart chambers.

When someone has heart failure, they overproduce the hormone aldosterone. Excess aldosterone causes heart remodelling. Vital, flexible heart muscle cells are replaced with more rigid connective tissue cells, with no useful function. As a result, the heart’s performance is greatly reduced. Spironolactone blocks the effect of aldosterone and could slow down or stop the remodelling processes that weaken the heart in heart failure.

SPIRIT-HF-DZHK8 is a double-blind phase III study. 35 study sites in Germany, as well as participants and hospitals in Austria, France, the Netherlands and Serbia are involved in the study.

More information: https://spirit-hf.dzhk.de/

SPIRIT-HF-DZHK8 - SPIRonolactone In the Treatment for Heart Failure (SPIRIT-HF-DZHK8)

Publications

There are no publications available yet.

Principal Investigators

Principal investigator: Frank Edelmann (Berlin) (vormals Burkert Pieske)

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.

Study information
SPIRIT-HF-DZHK8

Recruiting status
Recruiting complete, follow-up complete
Recruitment start
11.2018
Patients
733
1300
Clinical Trials Registrierung

ClinicalTrials.gov Identifier: NCT04727073

EudraCT Nr.: 2017-000697-11

Category
Guideline relevant study
DZHK Funding
€ 7.068.796
Links
https://spirit-hf.dzhk.de/

Operative contact:
Administrativ-coordinately:
Friederike Fenske
Medical-scientific:
Johannes Petutschnigg
Spirit-hf@charite.de

Studienzentren/Kontakt (PDF)

Do you want to associate your clinical trial with us?

Clinical studies that are not DZHK-financed can receive the status "DZHK-associated" if their objectives match our research interest. By associating, we support the study ideally, for example, by promoting recruitment through our network.

Please contact clinicalstudies@dzhk.de for further information.

Study Participation

Would you like to participate in a DZHK study or learn more about our clinical studies? The Patient Information Platform (PIP) informs patients, relatives and interested individuals about our clinical studies.

Learn more (German only)

Contact

Alexandra Klatt
Coordinator Clinical Research
Phone: +49 (0)30 3465 529 10 
alexandra.klatt@dzhk.de